- Published at
- by manilatimes.net
mixed
mixed
News for Prevail Therapeutics Inc (PRVL)
- Published at
- by globenewswire.com
mixedmixedEliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...- Published at
- by globenewswire.com
mixedmixedJasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...- Published at
- by marketscreener.com
mixedmixedPrecision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene...- Published at
- by seekingalpha.com
mixedmixedVoyager Therapeutics: A Shot At Making Gene Therapy Deliver Easier (NASDAQ:VYGR)
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why the best days are ahead for VYGR stock.VYGR.MXVYGRSRPTSLDBSIGHT.PARGNXPRVLPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEPASGNVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SAIONS.MXIONSIDP.DEGSGTFBIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBABBV34.SAABBV.MXABBV.BAABBV4AB.DE0RIM.L0L35.L0K9E.L0JDI.LZEG.DEUQ1.DETSHASGMOQURENBIXLLY.MXLLY.DELLY.BALLYLILY34.SAGBY.DEFOLD.MXFOLDFDMTDUL.DEBMRNAZNN.MXAZNCFAZN.LAZNALNYADVMABEOA1LN34.SA0R1D.L0Q1G.L0K6R.L0HNC.L0HF9.L0HD2.L0HA3.L0H7R.L0EE0.L0A4J.L- Published at
- by seekingalpha.com
mixedmixed- Published at
- by prnewswire.com
mixedmixedLilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth...- Published at
- by prnewswire.com
mixedmixedLilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by...- Published at
- by marketscreener.com
positivepositiveLilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately... | October 18, 2022- Published at
- by prnewswire.com
mixedmixedREGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in...- Published at
- by prnewswire.com
mixedmixedSolid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
Lilly's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew...- Published at
- by prnewswire.com
mixedmixedOmega Funds schließt den überzeichneten 650-Millionen-US-Dollar-Fonds VII ab, um in transformative Life-Science-Unternehmen zu investieren
/PRNewswire/ -- Omega Funds, ein führendes internationales Unternehmen für Risikokapital im Gesundheitswesen, das sich darauf konzentriert, Patienten...- Published at
- by prnewswire.com
neutralneutralOmega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
/PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it...- Published at
- by vcaonline.com
neutralneutral